AXGN

SEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · derivative · entry 2

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000063 · wf-form4_165428683027747.xml · nonDerivative · entry 1

Gold Mark Stephen · CIK 0001531332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

F2 · balance_after: The shares of common stock for Dr. Gold include 31,900 shares held directly, 159,575 shares held jointly by Dr. Gold and his wife, indirect ownership of 22,000 shares held by Dr. Gold's spouse in revocable trusts, and indirect ownership of 92,000 shares held by MJSK, Ltd., a decedent investment trust.

SEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 4

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F4 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 3

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F4 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · derivative · entry 2

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date.

SEC source: 0000805928-22-000062 · wf-form4_165428677346545.xml · nonDerivative · entry 1

Freitag Gregory Gene · CIK 0001492710 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 358,811

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022.

SEC source: 0000805928-22-000046 · wf-form4_164884650060564.xml · derivative · entry 2

Blackford Quentin S. · CIK 0001612451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,036 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2022, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. This grant was accelerated by Axogen's Board of Directors to vest upon departure.

SEC source: 0000805928-22-000046 · wf-form4_164884650060564.xml · nonDerivative · entry 1

Blackford Quentin S. · CIK 0001612451 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 30, 2022.

SEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 5

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,419

Underlying: Common Stock · 33,419 shares

Expires 2032-03-16

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 4

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,829

Underlying: Common Stock · 35,829 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · derivative · entry 3

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · nonDerivative · entry 2

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,343

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000030 · wf-form4_164763399971299.xml · nonDerivative · entry 1

Friedman Mark Louis · CIK 0001531023 · VP Regulatory Affairs & Policy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 5

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,738

Underlying: Common Stock · 23,738 shares

Expires 2032-03-16

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,450

Underlying: Common Stock · 25,450 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · derivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · nonDerivative · entry 2

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,578

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000028 · wf-form4_164763377704238.xml · nonDerivative · entry 1

DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · derivative · entry 7

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,348

Underlying: Common Stock · 30,348 shares

Expires 2032-03-16

F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · derivative · entry 6

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,536

Underlying: Common Stock · 32,536 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · derivative · entry 5

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · derivative · entry 4

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,734

Underlying: Common Stock · 4,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · nonDerivative · entry 3

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,283

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · nonDerivative · entry 2

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,522

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000036 · wf-form4_164763444302281.xml · nonDerivative · entry 1

MARTINEZ MARIA D. · CIK 0001633672 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,022

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 4

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,185

Underlying: Common Stock · 317,185 shares

Expires 2032-03-16

F5 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.

SEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 3

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,694

Underlying: Common Stock · 169,694 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,950

Underlying: Common Stock · 25,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000035 · wf-form4_164763430465185.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 966,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000034 · wf-form4_164763424502227.xml · derivative · entry 5

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,700

Underlying: Common Stock · 39,700 shares

Expires 2032-03-16

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-22-000034 · wf-form4_164763424502227.xml · derivative · entry 4

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,563

Underlying: Common Stock · 42,563 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000034 · wf-form4_164763424502227.xml · derivative · entry 3

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000034 · wf-form4_164763424502227.xml · nonDerivative · entry 2

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,180

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000034 · wf-form4_164763424502227.xml · nonDerivative · entry 1

Scopelianos Angelo · CIK 0001751541 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 5

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,576

Underlying: Common Stock · 60,576 shares

Expires 2032-03-16

F6 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.

F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.

SEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 4

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,910

Underlying: Common Stock · 62,910 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · derivative · entry 3

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · nonDerivative · entry 2

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,798

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000033 · wf-form4_164763418939739.xml · nonDerivative · entry 1

Sandberg Eric · CIK 0001764446 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 5

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,948

Underlying: Common Stock · 41,948 shares

Expires 2032-03-16

F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 4

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,973

Underlying: Common Stock · 44,973 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 3

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,127

Underlying: Common Stock · 2,563 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · nonDerivative · entry 2

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,073

F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · nonDerivative · entry 1

Ottinger Bradley · CIK 0001813381 · General Counsel and CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,721

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

F2 · balance_after: Includes 1,158 shares acquired under the Axogen stock purchase plan in 2021.

SEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 5

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,079

Underlying: Common Stock · 103,079 shares

Expires 2032-03-16

F6 · derivative.exercise_price: The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.

F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.

SEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 4

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,780

Underlying: Common Stock · 76,780 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · derivative · entry 3

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock Units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

SEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · nonDerivative · entry 2

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,584

F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

SEC source: 0000805928-22-000031 · wf-form4_164763405800552.xml · nonDerivative · entry 1

MARIANI PETER J · CIK 0001222357 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022.

SEC source: 0000805928-22-000029 · wf-form4_164763389248721.xml · derivative · entry 5

Donovan Michael Patrick · CIK 0001653918 · VP Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,745

Underlying: Common Stock · 34,745 shares

Expires 2032-03-16

F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.